Nyxoah's ACCCESS Trial Of Genio System Meets Primary Goals In CCC Sleep Apnea Patients; Shares Jump
Nyxoah SA (NYXH) reported positive results from its ACCCESS trial for the Genio system in treating sleep apnea with Complete Concentric Collapse (CCC). The study met primary efficacy and safety endpoints, with 77.2% AHI responder rate and 87.7% ODI responder rate. NYXH shares rose 29.14% in overnight trading.
How this was made
The 30-second read
Why it matters
The ACCCESS trial data represent the first positive pivotal results for the Genio system in CCC patients, potentially unlocking a larger market segment.
Market read
Positive trial data could drive short‑term stock rally and support longer‑term growth outlook.
What to watch
Regulatory timeline for FDA indication expansion could delay commercial impact.
Background
Nyxoah SA (NYXH) develops hypoglossal neurostimulation devices for obstructive sleep apnea.
Ticker impact
Nyxoah SA reported positive pivotal ACCCESS trial data for its Genio system, meeting primary efficacy and safety endpoints in CCC sleep apnea patients.
Potential upside of 10-15% over the next week as the market digests the data.
First disclosure of statistically significant efficacy in a niche patient group, expanding the device's potential indication.
Market effects
May broaden the neuromodulation market for sleep apnea therapies.
U.S. biotech sector could see modest uplift.
Limited to sleep‑apnea device niche.
Counterpoint
Skeptics may question long‑term adoption and reimbursement prospects.
Key entities
- CompanyNyxoah SA
Medical device maker focused on sleep apnea treatments.
- ProductGenio system
Battery‑free hypoglossal neurostimulation therapy.
